Consensus Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 24/09/2026 am IST			5-day change	1st Jan Change
516.34 ^USD	+0.26%		+0.33%	+13.89%

23/09	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
23/09	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT

Evolution of the Average Target: Vertex Pharmaceuticals Incorporated

Evolution of the Target Price: Vertex Pharmaceuticals Incorporated

Changes in Analyst Recommendations: Vertex Pharmaceuticals Incorporated

6f06b2e36d79c9cda4205224a4d63c.HWfWeM7tsAcELZaT7_Z2YjCgZcGnSr9dkSjE675iDUU.dQi3Moei4mVNWNH7mKcSNGLiLo_QDec34xq-mfBaNTFNApAco5_3VUhC9Q~c52d45e51dd6cb67d877a109a8acdf77

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

23/09	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
23/09	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
02/09	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
12/08	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
11/08	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
11/08	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
05/08	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
04/08	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
04/08	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
04/08	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
04/08	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
04/08	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
04/08	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
04/08	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
04/08	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
04/08	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
21/07	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
20/07	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
13/07	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
09/07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
08/07	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT
07/07	Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says	MT
07/07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $570 From $543, Maintains Outperform Rating	MT
07/07	Baird Adjusts Price Target on Vertex Pharmaceuticals to $350 From $330	MT
15/05	Daiwa Securities Adjusts PT on Vertex Pharmaceuticals to $555 From $561, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
VERTEX PHARMACEUTICALS INCORPORATED		+10.7%
ELI LILLY AND COMPANY		+13.27%
JOHNSON & JOHNSON		+3.24%
ABBVIE INC.		+5.05%
ROCHE HOLDING AG		+3.09%
NOVARTIS AG		+7.5%
ASTRAZENECA PLC	-	+25.05%
AMGEN INC.		-6.1%
GILEAD SCIENCES, INC.		+3.59%
NOVO NORDISK A/S		+18.84%
Average		+8.42%
Weighted average by Cap.		+8.51%